Reduced gastric accommodation in patients with Parkinson’s disease: A case series

2021 ◽  
Author(s):  
Jessica Atieh ◽  
Michael Camilleri
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series ◽  
Gastric Accommodation

scholarly journals Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson’s Disease

2021 ◽  
pp. 1-5
Author(s):  
Jonathan R. Isaacson ◽  
Salima Brillman ◽  
Nisha Chhabria ◽  
Stuart H. Isaacson
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Diagnosis ◽  
Clinical Decision Making ◽  
Photon Emission ◽  
Case Series ◽  
Emission Computed Tomography ◽  
Medication Therapy ◽  
Clinical Scenarios ◽  
The Impact

Background: The diagnosis of Parkinson’s disease (PD) is primarily clinical, but in cases of diagnostic uncertainty, evaluation of nigrostriatal dopaminergic degeneration (NSDD) by imaging of the dopamine transporter using DaTscan with single-photon emission computed tomography (SPECT) brain imaging may be helpful. Objective/Methods: In the current paper, we describe clinical scenarios for which DaTscan imaging was used in a prospective case series of 201 consecutive patients in whom a movement disorder specialist ordered DaTscan imaging to clarify NSDD. We describe the impact of DaTscan results on changing or confirming pre-DaTscan clinical diagnosis and on post-DaTscan treatment changes. Results/Conclusion: DaTscan imaging can be useful in several clinical scenarios to determine if NSDD is present. These include in patients with early subtle symptoms, suboptimal response to levodopa, prominent action tremor, drug-induced parkinsonism, and in patients with lower extremity or other less common parkinsonism clinical presentations. We also found DaTscan imaging to be useful to determine underlying NSDD in patients with PD diagnosis for 3-5 years but without apparent clinical progression or development of motor fluctuations. Overall, in 201 consecutive patients with clinically questionable NSDD, DaTscan was abnormal in 58.7% of patients, normal in 37.8%, and inconclusive in 3.5%. DaTscan imaging changed clinical diagnosis in 39.8% of patients and led to medication therapy changes in 70.1% of patients.

scholarly journals Impact of Footwear and Foot Deformities in patients with Parkinson's disease: A Case-Series Study

2021 ◽  
Vol 18 (2) ◽  
pp. 372-377
Author(s):  
Eloy Trillo Novo ◽  
Daniel López López ◽  
Carmen de Labra Pinedo ◽  
Marta Elena Losa Iglesias ◽  
Ricardo Becerro de Bengoa Vallejo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series ◽  
Foot Deformities ◽  
Case Series Study ◽  
Series Study

scholarly journals Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus

CNS Spectrums ◽  
2018 ◽  
Vol 23 (6) ◽  
pp. 402-413 ◽  
Author(s):  
Kevin J. Black ◽  
Henry Nasrallah ◽  
Stuart Isaacson ◽  
Mark Stacy ◽  
Rajesh Pahwa ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series ◽  
Published Data ◽  
Consensus Recommendation ◽  
Clinical Reason ◽  
Rebound Effects ◽  
Off Label ◽  
Receptor Interactions ◽  
Daily Dose

Patients with Parkinson’s disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP. How best to implement a switch to pimavanserin has not been clear, as there are no controlled trials or case series in the literature to provide guidance. An abrupt switch may interrupt partially effective treatment or potentially trigger rebound effects from antipsychotic withdrawal, whereas cross-taper involves potential drug interactions. A panel of experts drew from published data, their experience treating PDP, lessons from switching antipsychotic drugs in other populations, and the pharmacology of the relevant drugs, to establish consensus recommendations. The panel concluded that patients with PDP can be safely and effectively switched from atypical antipsychotics used off label in PDP to the recently approved pimavanserin by considering each agent’s pharmacokinetics and pharmacodynamics, receptor interactions, and the clinical reason for switching (efficacy or adverse events). Final recommendations are that such a switch should aim to maintain adequate 5-HT2A antagonism during the switch, thus providing a stable transition so that efficacy is maintained. Specifically, the consensus recommendation is to add pimavanserin at the full recommended daily dose (34 mg) for 2–6 weeks in most patients before beginning to taper and discontinue quetiapine or clozapine over several days to weeks. Further details are provided for this recommendation, as well as for special clinical circumstances where switching may need to proceed more rapidly.

Feasibility and safety of group exercises for individuals with Parkinson's disease: A case series

2017 ◽  
Vol 24 (5) ◽  
pp. 223-227
Author(s):  
Érica Guimarães Vianna ◽  
Erika de Carvalho Rodrigues ◽  
Carlos Henrique Ramos Horsczaruk ◽  
José Vicente Pereira Martins ◽  
Thiago Lemos ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series

2014 ◽  
Vol 39 (5) ◽  
pp. 564-566 ◽  
Author(s):  
M. H. N. Chagas ◽  
A. L. Eckeli ◽  
A. W. Zuardi ◽  
M. A. Pena-Pereira ◽  
M. A. Sobreira-Neto ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Eye Movement ◽  
Case Series ◽  
Rapid Eye Movement ◽  
Rapid Eye Movement Sleep ◽  
Behaviour Disorder ◽  
Sleep Behaviour

Reversal of Motor Symptoms in Parkinson’s Disease using Deep TMS with the H1 Coil: Longitudinal Case Series

2014 ◽  
Vol 7 (5) ◽  
pp. e25
Author(s):  
Aron Tendler ◽  
Elyssa Sisko ◽  
Abraham Zangen ◽  
Marilyn Turcone ◽  
Heather Allsup ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series ◽  
Motor Symptoms

Frequency of non‐motor symptoms and their impact on the quality of life in patients with Parkinson's disease: a prospective descriptive case series

2019 ◽  
Vol 20 (2) ◽  
pp. 206-211 ◽  
Author(s):  
Aydin Gulunay ◽  
Gul Y. Cakmakli ◽  
Mehmet I. Yon ◽  
Ersin K. Ulusoy ◽  
Mehmet Karakoc
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series ◽  
Motor Symptoms ◽  
Non Motor Symptoms

scholarly journals Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease: a case series

Cases Journal ◽  
2009 ◽  
Vol 2 (1) ◽  
pp. 7134 ◽  
Author(s):  
Kapil D Sethi ◽  
Robert A Hauser ◽  
Stuart H Isaacson ◽  
Terry McClain
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series

scholarly journals [123I]-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson’s disease: a case series study

2016 ◽  
Vol 56 (6) ◽  
pp. 400-406 ◽  
Author(s):  
Akane Yamada ◽  
Takenobu Murakami ◽  
Yongjin Kang ◽  
Yoichiro Iikuni ◽  
Akeshi Morimatsu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Series ◽  
Myocardial Scintigraphy ◽  
Case Series Study ◽  
Series Study
Sign in / Sign up

Export Citation Format

Share Document